SynthesisJournal of cancer research and clinical oncology2020

First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers.

Thierry Landre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.